<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02546492</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00063872</org_study_id>
    <nct_id>NCT02546492</nct_id>
  </id_info>
  <brief_title>Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar</brief_title>
  <acronym>TGActhar</acronym>
  <official_title>Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label safety and feasibility trial using Acthar® in addition to the
      investigators center-specific standard therapy, which could include increase in maintenance
      immunosuppression, high dose IVIG (2 g/Kg), and/or Rituximab, in patients with CAMR.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will receive Acthar® 40 units twice a week subcutaneously for 2 weeks. If the drug
      is well tolerated the dose will be increased to 80 units twice a week for another 22 weeks.
      The patients will be maintained on their center-specific standard maintenance regimen,
      typically consisting of Tacrolimus, mycephenolate mofetil/Sodium, and prednisone.

      After screening for the inclusion/exclusion criteria, the patients will be consented and
      enrolled in the study. The initial visit and subsequent study-related visits at 4, 8, 12, 24,
      36 and 52 weeks will include routine evaluation and physical examination and laboratory
      studies including CBC, electrolyte panel, eGFR, albumin, liver enzymes, and CNI/sirulimus
      drug level, according to the center's standard of care. DSA will be tested at week 24, and 52
      and patients will undergo a biopsy at week 52, as a part of the investigators standard of
      care. The biopsies will be evaluated by light and electron microscopy using standard
      histological Banff criteria, and staining for CD68.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy end point (Composite of graft loss, death, decrease in eGFR&gt;10%, and increase in proteinuria)</measure>
    <time_frame>12 months</time_frame>
    <description>Composite of graft loss, death, decrease in eGFR&gt;10%, and increase in proteinuria (defined as &gt;50% increase if baseline proteinuria &lt;2 g, or persistence of proteinuria &gt;2 g otherwise)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety (Serious adverse events)</measure>
    <time_frame>12 months</time_frame>
    <description>Serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft loss (Kidney allograft failure or death)</measure>
    <time_frame>12 months</time_frame>
    <description>Kidney allograft failure or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft function (&gt;10% decrease in eGFR)</measure>
    <time_frame>12 months</time_frame>
    <description>&gt;10% decrease in eGFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteniuria (Increase in proteinuria &gt;50% if baseline proteinuria&lt;2 g, or persistence of proteinuria &gt;2 g otherwise)</measure>
    <time_frame>12 months</time_frame>
    <description>Increase in proteinuria &gt;50% if baseline proteinuria&lt;2 g, or persistence of proteinuria &gt;2 g otherwise</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Transplant Glomerulopathy</condition>
  <arm_group>
    <arm_group_label>Acthar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study cohort. In this cohort Acthar gel will be administered to the enrolled patient with chrnic AMR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acthar gel</intervention_name>
    <description>Administration of the study drug in addition to the current maintenance immunosuppressive agents</description>
    <arm_group_label>Acthar</arm_group_label>
    <other_name>ACTH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Morphologic diagnosis of CAMR, by light &amp;/or electron microscopy any time after
             transplantation

          -  Current or previously documented donor-specific antibody (DSA) and/or focal or diffuse
             peritubular capillary C4d staining by immunohistochemistry

          -  eGFR&gt;25 ml/min

        Exclusion Criteria:

          -  Diagnosis of malignancy within a year prior to enrollment (except cured cutaneous
             basal cell or squamous cell carcinoma).

          -  Lack of evidence of antibody involvement

          -  Pregnancy, lactation, or refusal to use birth control in women of child bearing
             potential

          -  Active infection, or history of HIV

          -  History of liver or thoracic transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdolreza Haririan, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, Baltimore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abdolreza Haririan, MD, MPH</last_name>
    <phone>410-328-5720</phone>
    <email>ahariria@medicine.umaryland.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthew Weir, MD</last_name>
    <phone>410-328-5720</phone>
    <email>mweir@medicine.umaryland.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama School of Medicine, Alabama Transplant Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roslyn B Mannon, MD</last_name>
      <phone>205-934-7220</phone>
      <email>rmannon@uab.edu</email>
    </contact>
    <contact_backup>
      <last_name>Liz Hermon</last_name>
      <phone>205-996-9632</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Unniversity of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lalitha Anandagoda, MPH</last_name>
      <phone>410-328-5720</phone>
      <email>laanandagoda@som.umaryland.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 10, 2015</study_first_submitted>
  <study_first_submitted_qc>September 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <last_update_submitted>August 15, 2019</last_update_submitted>
  <last_update_submitted_qc>August 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, College Park</investigator_affiliation>
    <investigator_full_name>Abdoleza Haririan</investigator_full_name>
    <investigator_title>Medical director, Kidney and Pancreas Transplant Program</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

